Evaluation of vancomycin dosing regimens in Japanese patients exhibiting augmented renal clearance: A case series

Technical Summary: Evaluation of Vancomycin Dosing Regimens in Japanese Patients with Augmented Renal Clearance

Problem Statement
Augmented renal clearance (ARC), defined as a urinary creatinine clearance (CrCl) ≥ 130 mL/min/1.73 m², is a condition frequently observed in intensive care unit (ICU) settings, particularly among male, young, septic, or trauma patients. ARC significantly increases the clearance of renally excreted antibiotics, potentially leading to subtherapeutic concentrations. While vancomycin (VCM) dosing guidelines for Japanese patients with normal renal function recommend 20 mg/kg every 12 hours, and guidelines for patients with enhanced renal function (eCrCl ≥ 130 mL/min/1.73 m²) suggest escalating to 15–20 mg/kg every 8 hours, there is insufficient pharmacokinetic data regarding VCM behavior during ARC specifically within the Japanese population. The current evidence base relies heavily on expert opinion rather than robust clinical data, creating uncertainty about whether uniform high-dose regimens (15–20 mg/kg every 8 h) are appropriate for all ARC patients or if they risk exceeding the therapeutic window (AUC 400–600 µg·h/mL), thereby increasing the risk of nephrotoxicity.

Methodology
This study presents a case series of three male Japanese patients admitted to the ICU who were confirmed to have ARC. ARC was definitively diagnosed via 8-hour urinary CrCl measurements, rather than estimated values, to ensure diagnostic accuracy.

• Patients:
  • Case 1: 50s male, 78.7 kg, post-craniotomy for head trauma (CrCl 163.6 mL/min/1.73 m²).
  • Case 2: 40s male, 65 kg, post-craniotomy for head trauma (CrCl 146.6 mL/min/1.73 m²).
  • Case 3: 30s male, 60.5 kg, acute myeloid leukemia with respiratory deterioration (CrCl 224.2 mL/min/1.73 m²).
• Pharmacokinetic Analysis: Steady-state area under the time–concentration curve (AUCss) and predicted trough concentrations (Ctrough) were calculated using Bayesian estimation (BMs-Pod software version 8.09). The population parameters were based on a Japanese-specific pharmacokinetic model (vancomycinAdult.PAT2024).
• Dosing Simulations: For each patient, the study simulated AUCss and Ctrough values under three regimens:
  1. 20 mg/kg every 12 hours (standard for normal renal function).
  2. 15 mg/kg every 8 hours.
  3. 20 mg/kg every 8 hours.
• Data Collection: Blood concentrations were measured at specific time points (C-5 or C12 and Cpeak) to facilitate Bayesian estimation, adhering to ICU operational constraints.

Key Results
The study revealed significant variability in VCM pharmacokinetics among ARC patients, challenging the assumption that a uniform high-dose regimen is universally appropriate.

• Cases 1 and 2 (Moderate ARC): Both patients had CrCl values between 130 and 160 mL/min/1.73 m². Under the recommended 15–20 mg/kg every 8-hour regimens, the predicted AUCss values exceeded 600 µg·h/mL (ranging from 633.5 to 859.7 µg·h/mL), entering the range associated with nephrotoxicity. Specifically, Case 1 exhibited an AUCss of 664.8 µg·h/mL for 15 mg/kg every 8 h and 859.7 µg·h/mL for 20 mg/kg every 8 h, while Case 2 showed 633.5 µg·h/mL and 844.2 µg·h/mL respectively. Conversely, the standard regimen of 20 mg/kg every 12 hours yielded AUCss values of 562.8 and 573.1 µg·h/mL, respectively, which fell within the therapeutic target of 400–600 µg·h/mL.
• Case 3 (Severe ARC): This patient exhibited a markedly higher CrCl of 224.2 mL/min/1.73 m². Under the 15–20 mg/kg every 8-hour regimens, the AUCss values were 453.9 and 605.2 µg·h/mL. While the 20 mg/kg every 8-hour dose approached the upper limit, the 15 mg/kg every 8-hour dose resulted in an AUCss of 453.9 µg·h/mL, which is near the lower therapeutic threshold. Notably, the standard 20 mg/kg every 12-hour regimen resulted in an AUCss of only 403.5 µg·h/mL, barely meeting the minimum efficacy target.
• Nephrotoxicity: Case 3 developed nephrotoxicity on day 3, though the study notes that continuous monitoring of urinary CrCl was not performed until the end of treatment, making the precise timing of ARC resolution unclear.

Significance and Claims
The authors claim that this case series provides clinically meaningful evidence that the severity of ARC in Japanese patients dictates the necessary VCM dosing strategy, rendering a "one-size-fits-all" approach of 15–20 mg/kg every 8 hours potentially hazardous.

• Tailored Dosing: The paper argues that for patients with moderate ARC (CrCl ~130–160 mL/min/1.73 m²), the guideline-recommended high-frequency dosing may result in supratherapeutic AUCss levels and increased nephrotoxicity risk. In these cases, initiating treatment with the standard regimen for normal renal function (20 mg/kg every 12 h) may be more appropriate.
• Severity Dependence: Conversely, for patients with severe ARC (CrCl > 200 mL/min/1.73 m²), even the 15–20 mg/kg every 8-hour regimen may barely achieve therapeutic targets, suggesting a need for higher doses or more aggressive monitoring.
• Diagnostic Precision: The study emphasizes the importance of measuring actual urinary CrCl rather than relying on estimated values (eCrCl) to identify ARC, as diagnostic scores have shown low positive predictive value in Japanese ICU cohorts.
• Clinical Recommendations: The authors conclude that uniform dosing at 15–20 mg/kg every 8 hours should not be initiated without therapeutic drug monitoring (TDM). They recommend starting with standard doses for prophylactic use or milder infections in patients without markedly elevated CrCl, while reserving higher frequency dosing for severe infections or markedly elevated CrCl, always supported by early and frequent TDM to adjust for individual pharmacokinetic variability.

The paper maintains a modest tone, acknowledging limitations such as the small sample size, the inability to identify causative bacteria in some cases, and the lack of continuous CrCl monitoring throughout the entire treatment course. It positions itself as a descriptive report highlighting the need for further studies across a broader range of CrCl values to validate the hypothesis that VCM dosing must be stratified by the severity of ARC.